Latest Multiple Sclerosis Treatments - 5 Options

Multiple Sclerosis treatment is evolving fast, giving people more choices than ever.

In this guide, we break down five of the latest MS therapies, what benefits they offer, how effective they are, how they compare with older drugs, and practical steps to access them.

How we chose these 5 “latest” options

We focused on therapies approved in recent years or now widely adopted in practice, backed by large clinical trials and real-world data, and available (or accessible via referral) in many countries. For a broad background on disease-modifying therapies (DMTs), see the National MS Society’s overview of MS medications.

Every person’s MS is different. Effectiveness and risks vary by MS subtype, age, relapse history, MRI activity, comorbidities, and pregnancy plans. Decisions should be individualized with your MS neurologist and follow evidence-based guidance; a helpful starting point is the American Academy of Neurology DMT guideline summaries.

1) Ofatumumab (Kesimpta): self-injected anti-CD20 B-cell therapy

Benefits

High efficacy delivered as a once-monthly, at-home subcutaneous injection after initial loading.
Targets CD20+ B cells, a key driver of inflammatory MS activity.
No infusion chair time; convenient for people far from infusion centers.

Effectiveness

In the ASCLEPIOS I/II trials, ofatumumab significantly lowered annualized relapse rates (about 50% relative reduction) versus teriflunomide, cut new MRI lesion counts by more than 80%, and reduced risk of confirmed disability worsening. See the trial publication in the New England Journal of Medicine.

How it compares

Efficacy is comparable to infused anti-CD20 drugs (e.g., ocrelizumab, ublituximab). Compared with older platform therapies (interferons, glatiramer acetate), ofatumumab generally delivers larger reductions in relapses and MRI lesions. At-home dosing enhances convenience, though monitoring for infections, vaccination timing, and immunoglobulin levels remains essential.

How to access

Discuss eligibility with your neurologist; insurers often require documentation of relapses and/or MRI activity.
Baseline screening typically includes hepatitis B serology, CBC, and immunization review.
Medication is dispensed via specialty pharmacy; many programs include nurse support for first doses.
For coverage and cost resources, see the NMSS insurance and financial support page.

2) Ublituximab (Briumvi): faster-infusion anti-CD20

Benefits

High-efficacy B-cell therapy with a streamlined infusion schedule after loading.
Short infusion times (often about 1 hour for maintenance), reducing clinic time.

Effectiveness

The ULTIMATE I/II trials showed significantly lower relapse rates (ARR ~0.08–0.09 vs ~0.19 with teriflunomide) and fewer MRI lesions, with favorable disability outcomes. See the peer-reviewed results in the New England Journal of Medicine.

How it compares

Overall efficacy aligns with other anti-CD20 options. The key practical edge is the shorter infusion time. Safety is consistent with the class: infusion reactions (mostly early), infection risk including hypogammaglobulinemia over time, and vaccine planning considerations.

How to access

Initiation occurs at an infusion center with pre-infusion labs, vaccinations as needed, and premedication (e.g., steroids/antihistamines) per protocol.
Most insurers cover anti-CD20 therapies for relapsing MS with prior authorization; your clinic’s infusion coordinator can help navigate benefits.

3) Next-gen S1P modulators: ozanimod (Zeposia) and ponesimod (Ponvory)

Benefits

Oral, once-daily dosing after initial titration packs convenience into a pill.
Fewer first-dose cardiac monitoring requirements than older S1Ps for many patients.
Robust MRI lesion control with at-home administration.

Effectiveness

Ozanimod reduced relapses and MRI activity versus interferon beta‑1a in large trials (SUNBEAM, RADIANCE). Ponesimod outperformed teriflunomide for relapse reduction and MRI outcomes and also showed advantages on fatigue measures in OPTIMUM.

How it compares

These newer S1Ps generally offer improved convenience over first-generation fingolimod, with similar or better efficacy than older platform therapies. Compared with anti-CD20s, population-level relapse reductions may be somewhat smaller, but S1Ps avoid infusion logistics and may better fit some patients’ risk profiles or preferences.

How to access

Typical baseline work-up includes cardiac history review, ECG (as clinically indicated), ophthalmic exam for macular edema risk, liver tests, and varicella immunity check.
Specialty pharmacies manage dispensing; many insurers cover S1Ps for relapsing forms of MS with prior authorization.
Your clinician will advise on contraception, infection screening, and vaccine timing (notably live vaccines) before and during therapy.

4) Cladribine (Mavenclad): short-course immune reconstitution therapy

Benefits

Oral tablets given in two annual courses (a few dosing days each year) can provide durable effects for many patients.
Convenient between-course periods off continuous therapy.

Effectiveness

In the CLARITY trial, cladribine significantly reduced relapses (by ~58%) and MRI lesion activity versus placebo and lowered the risk of confirmed disability progression. See details in the NEJM publication.

How it compares

Effectiveness is generally higher than older platform therapies and competitive with other high-efficacy options for relapsing MS. It requires careful lymphocyte monitoring and infection risk management, and it’s contraindicated in pregnancy during treatment and for a period after; pregnancy planning and contraception are essential.

How to access

Access is via MS specialists familiar with immune reconstitution approaches.
Expect baseline labs (including lymphocyte counts), hepatitis screening, varicella-zoster immunity, age-appropriate cancer screening, and pregnancy testing/contraception counseling where relevant.
Payer criteria typically include documentation of disease activity and a safety monitoring plan.

5) Autologous hematopoietic stem cell transplantation (AHSCT)

Benefits

For highly active relapsing MS, AHSCT can induce deep disease quiescence (no evidence of disease activity) for many patients.
Single upfront procedure with potential long-term control without ongoing DMTs.

Effectiveness

Randomized and cohort studies, including the MIST trial, show substantial reductions in relapses and disability worsening versus conventional DMT escalation in aggressive relapsing MS. Professional societies have updated recommendations to define candidates and center standards; see EBMT guidance.

How it compares

Among the most potent options for inflammatory relapsing MS, AHSCT carries higher short-term risks (myeloablation, infection, hospitalization) and requires experienced centers. It’s generally not used for progressive MS without ongoing inflammatory activity.

How to access

Request referral to an AHSCT-experienced MS center; evaluation includes disease activity assessment and comorbidity screening.
Insurance coverage varies; many payers require documentation of highly active disease after high-efficacy DMTs. The NMSS provides an overview of stem cell therapy for MS and where it’s offered.

Quick comparison at a glance

Highest efficacy (inflammation control): Anti-CD20s (ofatumumab/ublituximab), AHSCT.
Oral convenience with solid efficacy: Ozanimod, ponesimod, cladribine (short-course).
Clinic time: Ofatumumab (home injection) minimizes visits; ublituximab offers short infusions; AHSCT requires hospitalization but is time-limited.
Monitoring needs: All require labs and infection screening; S1Ps add cardiac/eye checks; cladribine requires lymphocyte monitoring and pregnancy planning.

What’s on the horizon?

Bruton’s tyrosine kinase (BTK) inhibitors are in late-stage trials and aim to target both B cells and myeloid cells within the CNS. Several agents show promising MRI and relapse outcomes, but none are widely approved for MS at the time of writing. If you’re interested, ask your neurologist about clinical trials on ClinicalTrials.gov. For an accessible overview of BTK inhibitors in MS, see this peer-reviewed review.

How to access these treatments: a practical checklist

1) Book a comprehensive MS review

Schedule a visit with your MS specialist to review relapses, MRI trends, disability scores, infection history, vaccinations, pregnancy plans, and lifestyle goals. Bring your latest MRI and lab results.

2) Match the therapy to your goals and risk profile

Discuss trade-offs between efficacy, safety, monitoring, convenience, and family planning. High-efficacy early strategies may prevent disability for people with active disease; others may prioritize lower monitoring burdens.

3) Prep for coverage and logistics

Have your clinic submit prior authorization with clinical notes and MRI evidence.
Ask about foundation support and manufacturer programs; the NMSS lists resources.
Plan vaccinations before B-cell therapies or AHSCT when possible.

4) Set up monitoring

Clarify the lab schedule (CBC, liver enzymes, immunoglobulins), infection screening, and imaging cadence.
Know who to contact for new symptoms and how to handle missed doses or infusion delays.

5) Reassess regularly

Review treatment response at least annually: relapses, MRI activity, disability measures, tolerability, and life changes. Be ready to switch if disease activity breaks through or if your goals evolve.

Key takeaway

Today’s Multiple Sclerosis treatments offer more power and flexibility than ever—from self-injected and oral options to hospital-based AHSCT. Work with your neurologist to align the right therapy to your disease activity and life goals, and use the steps above to access care efficiently.